Preetam Shah is CFO & CBO at Cidara Therapeutics, Inc. (CDTX). They have made 5 open-market trades across 2 companies since 2019, most recently 2026-02-02.
CIK 0001787403
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $77K since 2019, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CDTX | SELL | 2024-03-11 | 2024-03-12 | $0.67 | $13K | +15.9% | +28.8% | +0.1% |
| CDTX | SELL | 2023-03-13 | 2023-03-13 | $1.53 | $10K | -17.3% | -37.0% | -28.9% |
| CDTX | SELL | 2022-09-19 | 2022-09-19 | $0.77 | $12K | -14.5% | -25.4% | -36.6% |
| CDTX | BUY | 2021-11-12 | 2021-11-15 | $1.54 | $31K | -11.4% | -26.5% | -51.7% |
| BCLI | BUY | 2019-12-24 | 2019-12-27 | $3.96 | $46K | +5.2% | +1.0% | +18.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.